Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R A Maas

Showing results (1-10 of 22) with videos related to

Pageof 3
Sort By:
Immunology Today|February 1, 1992
T cells and tumorsR A Maas, H F Dullens, W Den Otter
Cancer Immunology, Immunotherapy : CII|January 1, 1993
Interleukin-2 in cancer treatment: disappointing or (still) promising? A reviewR A Maas, H F Dullens, W Den Otter
In Vivo (Athens, Greece)|November 1, 1991
Mechanisms of tumor regression induced by low doses of interleukin-2R A Maas, H F Dullens, W Den Otter
The British Journal of Dermatology|January 1, 1993
Are atopic disorders due to a TH2 clone?W den Otter, J W Koten, R A Maas, et al.
Avian Pathology : Journal of the W.V.P.A|May 17, 2008
The use of homologous virus in the haemagglutination-inhibition assay after vaccination with Newcastle disease virus strain La Sota or Clone30 leads to an over estimation of protective serum antibody titresR A Maas, H L Oei, S Kemper, et al.
Journal of Clinical Pathology|July 1, 1996
Iododeoxyuridine labelling of S-phase fraction in fine needle aspirates from breast carcinomasR A Maas, P F Bruning, A J Breedijk, et al.
Cancer Immunology, Immunotherapy : CII|January 1, 1991
Intratumoral low-dose interleukin-2 induces rejection of distant solid tumourR A Maas, D H Van Weering, H F Dullens, et al.
Avian Diseases|December 28, 1999
Dose-response effects of inactivated Newcastle disease vaccines: influence of serologic assay, time after vaccination, and type of chickensR A Maas, H L Oei, S Venema-Kemper, et al.
Cancer Research|December 15, 1989
Immunotherapy of mice with a large burden of disseminated lymphoma with low-dose interleukin 2R A Maas, H F Dullens, W H De Jong, et al.
Cancer Letters|October 20, 1995
Growth arrest associated changes of mRNA levels in breast cancer cells measured by semi-quantitative RT-PCR: potential early indicators of treatment responseR A Maas, P F Bruning, B Top, et al.
Pageof 3

Showing results (1-10 of 22) with videos related to

Sort By:
Pageof 3
Immunology Today|February 1, 1992
T cells and tumorsR A Maas, H F Dullens, W Den Otter
Cancer Immunology, Immunotherapy : CII|January 1, 1993
Interleukin-2 in cancer treatment: disappointing or (still) promising? A reviewR A Maas, H F Dullens, W Den Otter
In Vivo (Athens, Greece)|November 1, 1991
Mechanisms of tumor regression induced by low doses of interleukin-2R A Maas, H F Dullens, W Den Otter
The British Journal of Dermatology|January 1, 1993
Are atopic disorders due to a TH2 clone?W den Otter, J W Koten, R A Maas, et al.
Avian Pathology : Journal of the W.V.P.A|May 17, 2008
The use of homologous virus in the haemagglutination-inhibition assay after vaccination with Newcastle disease virus strain La Sota or Clone30 leads to an over estimation of protective serum antibody titresR A Maas, H L Oei, S Kemper, et al.
Journal of Clinical Pathology|July 1, 1996
Iododeoxyuridine labelling of S-phase fraction in fine needle aspirates from breast carcinomasR A Maas, P F Bruning, A J Breedijk, et al.
Cancer Immunology, Immunotherapy : CII|January 1, 1991
Intratumoral low-dose interleukin-2 induces rejection of distant solid tumourR A Maas, D H Van Weering, H F Dullens, et al.
Avian Diseases|December 28, 1999
Dose-response effects of inactivated Newcastle disease vaccines: influence of serologic assay, time after vaccination, and type of chickensR A Maas, H L Oei, S Venema-Kemper, et al.
Cancer Research|December 15, 1989
Immunotherapy of mice with a large burden of disseminated lymphoma with low-dose interleukin 2R A Maas, H F Dullens, W H De Jong, et al.
Cancer Letters|October 20, 1995
Growth arrest associated changes of mRNA levels in breast cancer cells measured by semi-quantitative RT-PCR: potential early indicators of treatment responseR A Maas, P F Bruning, B Top, et al.
Pageof 3